---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-25-000128"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:28:12.573451+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ivonescimab HARMONi PFS HR 0.52, NMPA approval; Summit Q2 net loss $565.7M

## Summary
- HARMONi PFS HR 0.52 (p<0.00001); OS trend HR 0.79 (p=0.057); BLA filing planned.
- Ivonescimab monotherapy approved by NMPA for 1L PD-L1 positive advanced NSCLC in China.
- HARMONi-6: ivonescimab + chemo superior to tislelizumab + chemo in 1L squamous NSCLC.
- Cash & equivalents $297.9M (down from $412.3M); ATM offering of up to $360M.
- GAAP net loss $565.7M ($0.76/sh); non-GAAP $86.9M ($0.12/sh); stock modification $466.6M non-cash.

## SEC filing metadata
- accession: 0001599298-25-000128
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929825000128/0001599298-25-000128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929825000128/smmt-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-25-000128
- JSON: https://secwatch.observer/filing/0001599298-25-000128.json
- Plain text: https://secwatch.observer/filing/0001599298-25-000128.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.